A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Trial Profile

A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases; Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms SENSCIS
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Nov 2017 Planned End Date changed from 28 Dec 2018 to 28 Nov 2018.
    • 28 Nov 2017 Planned primary completion date changed from 30 Nov 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top